Valuation: Mineralys Therapeutics, Inc.

Market Cap 1.61B 1.43B 1.32B 1.2B 2.25B 152B 2.29B 15.73B 6.34B 80.31B 6.03B 5.9B 254B P/E 2026 *
-4.05x
P/E 2027 * -7.31x
Enterprise Value 1.35B 1.21B 1.11B 1.01B 1.89B 128B 1.93B 13.22B 5.33B 67.53B 5.07B 4.96B 213B EV / Sales 2026 *
-
EV / Sales 2027 * 17.2x
Free-Float
97.47%
Yield 2026 *
-
Yield 2027 * -
1 day-14.47%
1 week-24.33%
Current month-14.47%
1 month-34.44%
3 months-39.07%
6 months-46.86%
Current year-57.15%
1 week 15.42
Extreme 15.42
22.48
1 month 15.42
Extreme 15.42
24
Current year 15.42
Extreme 15.42
37.7
1 year 15.42
Extreme 15.42
47.65
3 years 5.85
Extreme 5.85
47.65
5 years 5.85
Extreme 5.85
47.65
10 years 5.85
Extreme 5.85
47.65
Manager TitleAgeSince
Chief Executive Officer 62 01/11/2020
Director of Finance/CFO 48 01/03/2022
Chief Tech/Sci/R&D Officer 72 10/08/2026
Director TitleAgeSince
Director/Board Member 62 -
Chairman 49 31/05/2019
Director/Board Member 58 01/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Sell

Chief Executive Officer

-75,000 0.0986%
22/09/26
Catalys Pacific LLC
SellCompany -104,320 0.1371%
21/09/26 Exercice

Chief Commercial Officer

22,314 0.0293%
Change 5-day change 1-year change 3-year change Capi.($)
-14.47%-24.33%-61.94%+100.65% 1.61B
-2.37%-4.19%+39.49%+63.21% 63.77B
-2.87%+0.23%+11.11%+68.89% 56.37B
+0.62%+2.60%+16.96%+103.45% 54.62B
-3.33%-7.49%+19.39%+43.57% 44.06B
-2.45%-4.33%+16.36%+99.27% 42.11B
-1.64%+0.63%+219.80%+824.67% 41B
-5.47%+39.86%+101.20%+80.57% 34.92B
+0.21%-1.23%+14.81%+47.35% 32.82B
-2.90%+17.05%-42.35%+337.41% 24.7B
Average -3.47%+5.80%+33.48%+176.90% 39.6B
Weighted average by Cap. -2.21%+5.57%+44.20%+167.55%

Financials

2026 *2027 *
Net sales - 84.31M 75.27M 69.07M 62.83M 118M 7.98B 120M 825M 333M 4.21B 316M 310M 13.31B
Net income -383M -342M -313M -285M -534M -36.21B -545M -3.74B -1.51B -19.11B -1.44B -1.4B -60.37B -223M -199M -182M -166M -311M -21.07B -317M -2.18B -878M -11.12B -835M -818M -35.13B
Net Debt -256M -228M -210M -191M -357M -24.22B -365M -2.5B -1.01B -12.78B -960M -940M -40.38B -160M -143M -131M -119M -224M -15.16B -228M -1.57B -631M -8B -601M -588M -25.27B
Projected Income Statement - Annual - Mineralys Therapeutics, Inc.
Logo Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.
Employees
76
Date Price Change Volume
02/11/26 $15.55 -14.47% 4,575,809
30/10/26 $18.18 -14.41% 3,979,591
29/10/26 $21.24 -0.65% 2,077,152
28/10/26 $21.38 +1.18% 1,543,455
27/10/26 $21.13 +2.77% 3,199,926
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Mineralys Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
15.55USD
Average target price
45.22USD
Spread / Average Target
+190.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mineralys Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. MLYS Stock